These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11855395)

  • 1. Screening for diabetes in general practice. Population screening for diabetes is cost effective.
    Higson N
    BMJ; 2002 Feb; 324(7334):426. PubMed ID: 11855395
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of type 2 diabetes screening: results from recently published studies.
    Icks A; Rathmann W; Haastert B; John J; Löwel H; Holle R; Giani G;
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S167-71. PubMed ID: 16032536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Screening and intervention. A strategy in type 2 diabetes?].
    Jørgensen T; Glümer C; Borch-Johnsen K
    Ugeskr Laeger; 2002 Apr; 164(16):2135-9. PubMed ID: 11989055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding undiagnosed type 2 diabetes: is it worth the effort?
    Engelgau MM; Narayan KM
    Eff Clin Pract; 2001; 4(6):281-3. PubMed ID: 11769302
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost effectiveness of screening of all newly recruited employees for diabetes at a tertiary care hospital.
    Ali NS; Khuwaja AK
    J Ayub Med Coll Abbottabad; 2007; 19(2):23-5. PubMed ID: 18183713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany.
    Schaufler TM; Wolff M
    Appl Health Econ Health Policy; 2010; 8(3):191-202. PubMed ID: 20408603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we screen for type 2 diabetes: Yes.
    Khunti K; Davies M
    BMJ; 2012 Jul; 345():e4514. PubMed ID: 22777029
    [No Abstract]   [Full Text] [Related]  

  • 8. Maximizing efficiency and cost-effectiveness of Type 2 diabetes screening: the AusDiab study.
    Chen L; Magliano DJ; Balkau B; Wolfe R; Brown L; Tonkin AM; Zimmet PZ; Shaw JE
    Diabet Med; 2011 Apr; 28(4):414-23. PubMed ID: 21392062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
    Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
    Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical screening in general practice: call and recall.
    Ridsdale LL
    J R Coll Gen Pract; 1987 Jun; 37(299):257-9. PubMed ID: 3129556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost benefit of screening for type 1 diabetes. A futuristic scenario].
    Lévy-Marchal C
    Diabete Metab; 1993 Dec; 19(5 Suppl):538-45. PubMed ID: 8206195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost analysis of community screening for diabetes in the central Wisconsin Medicare population (results from the MetaStar pilot project in Wausau).
    Lee DS; Remington P; Madagame J; Blustein J
    WMJ; 2000 Jun; 99(3):39-43. PubMed ID: 10927980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How frequently should patients with type 2 diabetes mellitus be screened for retinopathy?
    Murphy C; Newton W
    J Fam Pract; 2000 May; 49(5):395-6. PubMed ID: 10836765
    [No Abstract]   [Full Text] [Related]  

  • 14. [Opportunistic screening for diabetes in primary health care. Life style changes can prevent diabetes mellitus among individuals at risk].
    Hagström B
    Lakartidningen; 2002 Apr; 99(16):1852. PubMed ID: 12043490
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating the impact of a national pilot screening programme for type 2 diabetes in deprived areas of England.
    Goyder E; Wild S; Fischbacher C; Carlisle J; Peters J
    Fam Pract; 2008 Oct; 25(5):370-5. PubMed ID: 18765406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uremia (end-stage renal disease): how cost-effective are preventive strategies?
    Glassock RJ
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S131-4. PubMed ID: 20797562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discover diabetes: screening for diabetes mellitus in the Waikato.
    Lawrenson RA; Dunn PJ; Jury D; Sceats J
    N Z Med J; 1993 Dec; 106(969):522-4. PubMed ID: 8183493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost effectiveness of universal diabetes screening.
    Manag Care Interface; 2004 Oct; 17(10):59-60. PubMed ID: 15535080
    [No Abstract]   [Full Text] [Related]  

  • 19. Using an economic model of diabetes to evaluate prevention and care strategies in Australia.
    Colagiuri S; Walker AE
    Health Aff (Millwood); 2008; 27(1):256-68. PubMed ID: 18180502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.